StockData
Incyte Corp logo

Incyte Corp (INCY) stock

INCYNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 13/3091% above fair value
$119.09−1.18 (-0.98%)

Close on Nov 17, 2026Market cap $24.27BP/E 63.3Yield –

Incyte r&d expenses

Research and development expenses are spending on new products and technology.

Incyte's R&D Expenses for the twelve months ending Sep 30, 2026 was $3.44B, up 80.4% year over year. For fiscal 2025 it was $2.05B, down 21.4% from the year before. Over ten years it grew 15.6% a year on average. The highest annual figure on record is $2.61B in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.05B-21.4%
FY2024Dec 31, 2024$2.61B+60.2%
FY2023Dec 31, 2023$1.63B+2.6%
FY2022Dec 31, 2022$1.59B+8.8%
FY2021Dec 31, 2021$1.46B-34.2%
FY2020Dec 31, 2020$2.22B+92.0%
FY2019Dec 31, 2019$1.15B-3.7%
FY2018Dec 31, 2018$1.20B-9.7%
FY2017Dec 31, 2017$1.33B+127.9%
FY2016Dec 31, 2016$581.86M+21.3%
FY2015Dec 31, 2015$479.51M+38.0%
FY2014Dec 31, 2014$347.52M+33.4%
FY2013Dec 31, 2013$260.44M+23.8%
FY2012Dec 31, 2012$210.39M+17.7%
FY2011Dec 31, 2011$178.71M+44.3%
FY2010Dec 31, 2010$123.88M+3.7%
FY2009Dec 31, 2009$119.44M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.79B+253.7%
Q2 FY2026Jun 30, 2026$516.95M+4.5%
Q1 FY2026Mar 31, 2026$515.90M+18.0%
Q4 FY2025Dec 31, 2025$611.37M+31.2%
Q3 FY2025Sep 30, 2025$506.58M-11.6%
Q2 FY2025Jun 30, 2025$494.92M-56.5%
Q1 FY2025Mar 31, 2025$437.28M+1.9%
Q4 FY2024Dec 31, 2024$466.03M+4.8%
Q3 FY2024Sep 30, 2024$573.17M+52.6%
Q2 FY2024Jun 30, 2024$1.14B+184.1%
Q1 FY2024Mar 31, 2024$429.26M+5.6%
Q4 FY2023Dec 31, 2023$444.49M-11.3%
Q3 FY2023Sep 30, 2023$375.71M-2.2%
Q2 FY2023Jun 30, 2023$400.75M+15.4%
Q1 FY2023Mar 31, 2023$406.64M+15.1%
Q4 FY2022Dec 31, 2022$501.36M+6.0%
Q3 FY2022Sep 30, 2022$384.01M+14.6%
Q2 FY2022Jun 30, 2022$347.20M+1.1%
Q1 FY2022Mar 31, 2022$353.37M+15.1%
Q4 FY2021Dec 31, 2021$472.83M+16.5%
Q3 FY2021Sep 30, 2021$334.95M-23.5%
Q2 FY2021Jun 30, 2021$343.51M+19.9%
Q1 FY2021Mar 31, 2021$306.90M-71.7%
Q4 FY2020Dec 31, 2020$405.95M+29.8%
Q3 FY2020Sep 30, 2020$438.11M+55.7%
Q2 FY2020Jun 30, 2020$286.60M-1.0%
Q1 FY2020Mar 31, 2020$1.09B+301.1%
Q4 FY2019Dec 31, 2019$312.87M+2.8%
Q3 FY2019Sep 30, 2019$281.34M-3.8%
Q2 FY2019Jun 30, 2019$289.36M-2.9%
Q1 FY2019Mar 31, 2019$270.55M-10.7%
Q4 FY2018Dec 31, 2018$304.24M-31.9%
Q3 FY2018Sep 30, 2018$292.53M+8.5%
Q2 FY2018Jun 30, 2018$298.09M+47.7%
Q1 FY2018Mar 31, 2018$303.10M-25.7%
Q4 FY2017Dec 31, 2017$446.87M+176.6%
Q3 FY2017Sep 30, 2017$269.56M–
Q2 FY2017Jun 30, 2017$201.79M–
Q1 FY2017Mar 31, 2017$407.92M–
Q4 FY2016Dec 31, 2016$161.59M–

More Incyte figures

See a number that looks wrong?